Drug recall · December 11, 2024
Duloxetine Delayed-Release Capsules recall
Why: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Duloxetine Delayed-Release Capsules, USP, 60 mg, Rx only, 1,000 count bottle, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories NDC 68001-415-08
- Lots / codes
Lot, expiry: DT6022159A, DT6022167A, DT6022168A, exp 11/30/2024; Lot DT6023034A, 12/31/2024; Lots DT6023050A, DT6023051A, DT6023063A, DT6023067A, exp 01/31/2025; Lots DT6023073A, DT6023072A, exp 02/28/2025
- Quantity
- 8,561 bottles
- Company
- Amerisource Health Services LLC, Columbus, OH
- Distribution
- PA, OH, PR
- Initiated
- November 14, 2024 · Voluntary: Firm initiated
- Classified
- December 3, 2024
- Reported
- December 11, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Duloxetine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.